Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 AME and absolute bioavailability study of leriglitazone in healthy male volunteers
NL-OMON51365Phase 1Completed
- Sponsor
- Minoryx Therapeutics
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of leriglitazone in adrenoleukodystrophy (ALD) and Friedreich ataxia (FA) (2 arms), sponsored by Minoryx Therapeutics. Primary endpoints: Adverse events, Clinical laboratory parameters and 3 more. Started Mar 2022; status: completed.
02
Drugs
leriglitazone
03
Conditions
adrenoleukodystrophy (ALD)Friedreich ataxia (FA)
Beyond the preview
Go deeper on NL-OMON51365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51365.